Schrage N, Hille K, Cursiefen C
Augenklinik, Kliniken Merheim der Stadt Köln, ACTO e. V., RWTH Aachen, Aachen, Deutschland.
Ophthalmologe. 2014 Nov;111(11):1010-8. doi: 10.1007/s00347-013-3009-5.
Although corneal transplant surgery in avascular normal risk eyes is becoming even more minimally invasive and successful, treatment options for difficult to treat patients with high risk eyes are still limited. In these cases HLA typed allogeneic transplants and artificial corneas (keratoprostheses) can be used.
This article combines a review of the literature in PubMed and own clinical experiences on the use of artificial corneas in high risk eyes. Osteo-odontokeratoprosthesis (OOKP), Boston Kpro, Miro Cornea® and KeraKlear® corneas were used as clinical keratoprostheses.
Worldwide, the most experience exists for the use of Boston Kpro and OOKP in high risk eyes. Miro Cornea® and KeraKlear® are new procedures where only preliminary results are available and further evaluation is necessary. The longest experience and best anatomical long-term results have been achieved with OOKPs. Comparable cohorts are available for the Boston Kpro. The function of all keratoprostheses is threatened by secondary glaucoma. Implantation of the KeraKlear® prosthesis remains difficult. The Miro Cornea® shows an initially stable integration behavior.
Keratoprostheses, such as the Boston Kpro and OOKP are valid treatment options for eyes which are not open to therapy with allogeneic corneal transplantation. Modern implants such as KeraKlear® prosthesis and Miro Cornea® need further prospective clinical evaluation.
尽管在无血管的正常风险眼中进行角膜移植手术正变得越来越微创且成功,但对于高风险眼的难治性患者,治疗选择仍然有限。在这些情况下,可以使用 HLA 分型的同种异体移植和人工角膜(角膜假体)。
本文结合了 PubMed 上的文献综述以及自身在高风险眼中使用人工角膜的临床经验。骨牙角膜假体(OOKP)、波士顿 Kpro、Miro Cornea® 和 KeraKlear® 角膜被用作临床角膜假体。
在全球范围内,在高风险眼中使用波士顿 Kpro 和 OOKP 的经验最为丰富。Miro Cornea® 和 KeraKlear® 是新的手术方法,目前只有初步结果,需要进一步评估。OOKP 取得了最长的经验和最佳的解剖学长期效果。波士顿 Kpro 有可比的队列。所有角膜假体的功能都受到继发性青光眼的威胁。KeraKlear® 假体的植入仍然困难。Miro Cornea® 显示出最初稳定的整合行为。
角膜假体,如波士顿 Kpro 和 OOKP,是同种异体角膜移植无法治疗的眼睛的有效治疗选择。现代植入物,如 KeraKlear® 假体和 Miro Cornea®,需要进一步的前瞻性临床评估。